Natera Stock

Natera Enterprise Value

The Enterprise Value (EV) of Natera (NTRA) as of Aug 26, 2026 is 27.45 B USD. In the previous year, Enterprise Value (EV) was 27.64 B USD — a change of -0.68% (lower).

Enterprise Value

27.45 BUSD

YoY

-0.68%

Last updated:

Enterprise Value (EV) of Natera is 2026 27.45 B USD. Enterprise Value (EV) of Natera was 2025 27.64 B USD. It decreases by -0.68% lower compared to the previous year.

The Natera Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
28.50 B USD
Jan 1, 2019
28.21 B USD
Jan 1, 2020
28.04 B USD
Jan 1, 2021
27.94 B USD
Jan 1, 2022
27.99 B USD
Jan 1, 2023
28.01 B USD
Jan 1, 2024
27.64 B USD
Jan 1, 2025
27.45 B USD
The Natera Enterprise Value history
YEAREnterprise ValueYoY
27.45 BUSD-0.68%
27.64 BUSD-1.33%
28.01 BUSD+0.07%
27.99 BUSD+0.17%
27.94 BUSD-0.35%
28.04 BUSD-0.59%
28.21 BUSD-1.01%
28.50 BUSD-0.12%
28.53 BUSD+0.35%
28.43 BUSD+0.32%
28.34 BUSD-0.45%
28.47 BUSD
Access this data via the Eulerpool API

Natera Stock analysis

What does Natera do? Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community. Natera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natera stock

Enterprise Value (EV) of Natera is 27.45 B USD in 2026.

Enterprise Value (EV) of Natera changed from 27.64 B USD to 27.45 B USD, representing a -0.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Natera since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Natera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Natera

All Key Metrics — Natera